Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.45 |
| ▸ | IKZF3 | Q9UKT9 | 5/20 | 0.44 |
| ▸ | TNF | P01375 | 4/20 | 0.44 |
| ▸ | IL1B | P01584 | 4/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.44 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.36 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7856696 | 0.85 | CRBN (0.45) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL7850526 | 0.85 | CRBN (0.62) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL10074217 | 0.84 | CRBN (0.43) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL7858459 | 0.81 | CRBN (0.42) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL7857404 | 0.81 | CRBN (0.42) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL7850522 | 0.81 | CRBN (0.42) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL21214932 | 0.79 | CRBN (0.59) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL30009197 | 0.77 | CRBN (0.75) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL476914 | 0.77 | CRBN (0.75) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL2032577 | 0.77 | CRBN (0.75) | CRBNIKZF3TNFIL1BDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522899-B2 | Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof | NANJIAN CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., LTD (CN) | 2016-12-20 | — | — | US | disclosed |
| US-20150284359-A1 | Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2015-10-08 | — | — | US | disclosed |
| US-20150284329-A1 | Methods for synthesizing 3-(Substituted Dihydroisoindolinone-2-YI)-2, 6-Dioxopiperidine, and intermediates thereof | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2015-10-08 | — | — | US | disclosed |
| US-9085530-B2 | Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2015-07-21 | — | — | US | disclosed |
| US-20120077982-A1 | Methods for Synthesizing 3-(Substituted Dihydroisoindolinone-2-YL)-2, 6-Dioxopiperidine, and Intermediates Thereof | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284329-A1 | Methods for synthesizing 3-(Substituted Dihydroisoindolinone-2-YI)-2, 6-Dioxopiperidine, and intermediates thereof | DHPS, QDPR, FDPS | CRBN 4352/4885IKZF3 1195/4885TNF 1790/4885 |
| US-20120077982-A1 | Methods for Synthesizing 3-(Substituted Dihydroisoindolinone-2-YL)-2, 6-Dioxopiperidine, and Intermediates Thereof | DHPS, QDPR, FDPS | CRBN 4078/4885IKZF3 1593/4885TNF 2065/4885 |
| US-20150284359-A1 | Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof | DHPS, QDPR, FDPS | CRBN 4078/4885IKZF3 1593/4885TNF 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.